AstraZeneca plc (NYSE:AZN) shares gapped up prior to trading on Thursday . The stock had previously closed at $42.51, but opened at $43.57. AstraZeneca shares last traded at $44.61, with a volume of 4,158,074 shares changing hands.
Several analysts recently commented on AZN shares. Argus raised their target price on AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. DZ Bank cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. Finally, ValuEngine cut AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company. AstraZeneca currently has a consensus rating of “Hold” and an average price target of $45.96.
The company has a market capitalization of $111.54 billion, a price-to-earnings ratio of 25.79, a PEG ratio of 1.44 and a beta of 0.49. The firm has a 50-day moving average price of $44.32 and a 200-day moving average price of $41.22. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 1.19.
Several hedge funds have recently modified their holdings of AZN. Cornerstone Advisors Inc. increased its position in shares of AstraZeneca by 61.3% during the 1st quarter. Cornerstone Advisors Inc. now owns 1,534 shares of the company’s stock valued at $62,000 after purchasing an additional 583 shares during the period. Toronto Dominion Bank increased its position in shares of AstraZeneca by 888.9% during the 1st quarter. Toronto Dominion Bank now owns 48,725 shares of the company’s stock valued at $1,970,000 after purchasing an additional 43,798 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of AstraZeneca during the 1st quarter valued at $635,000. Buckingham Capital Management Inc. boosted its stake in shares of AstraZeneca by 113.2% during the 1st quarter. Buckingham Capital Management Inc. now owns 58,095 shares of the company’s stock worth $2,349,000 after acquiring an additional 30,843 shares in the last quarter. Finally, Keybank National Association OH boosted its stake in shares of AstraZeneca by 9.5% during the 1st quarter. Keybank National Association OH now owns 64,065 shares of the company’s stock worth $2,590,000 after acquiring an additional 5,582 shares in the last quarter. Institutional investors own 17.52% of the company’s stock.
About AstraZeneca (NYSE:AZN)
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Limitations to arbitrage trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.